Cargando…
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
INTRODUCTION: Black or African American (black/AA) patients with multiple sclerosis (MS) are reported to exhibit greater disease severity compared with non-black or non-AA patients. Whether differences exist in response to MS disease-modifying therapies remains uncertain, as MS clinical trials have...
Autores principales: | Williams, Mitzi J., Amezcua, Lilyana, Okai, Annette, Okuda, Darin T., Cohan, Stanley, Su, Ray, Parks, Becky, Mendoza, Jason P., Lewin, James B., Jones, Cynthia C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606389/ https://www.ncbi.nlm.nih.gov/pubmed/32472386 http://dx.doi.org/10.1007/s40120-020-00193-5 |
Ejemplares similares
-
Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Chinea, Angel, et al.
Publicado: (2020) -
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2023) -
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
por: Amezcua, Lilyana, et al.
Publicado: (2023) -
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015) -
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation
por: Wright, Katy, et al.
Publicado: (2017)